Cytokinetics Stock News

Here are the five best biotech ETFs to invest in right now.

Prudential Financial Inc. cut its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 4.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 77,198 shares of the biopharmaceutical companys stock after selling 3,617 shares during the quarter. Prudential Financial Inc. owned about 0.09% of Cytokinetics worth []

Wall Street brokerages expect Cytokinetics, Incorporated (NASDAQ:CYTK) to post ($0.82) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have issued estimates for Cytokinetics earnings, with the lowest EPS estimate coming in at ($0.93) and the highest estimate coming in at ($0.66). Cytokinetics posted earnings per share of ($0.62) in the same []

Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sandford D. Smith sold 29,032 shares of the businesss stock in a transaction dated Friday, November 19th. The stock was sold at an average price of $41.21, for a total transaction of $1,196,408.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this []

Credit Suisse AG lowered its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 19.8% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 97,567 shares of the biopharmaceutical companys stock after selling 24,041 shares during the quarter. Credit Suisse AG owned about 0.12% of Cytokinetics worth $1,931,000 []

Nuveen Asset Management LLC reduced its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 13.0% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 257,432 shares of the biopharmaceutical companys stock after selling 38,434 shares during the period. Nuveen Asset Management LLC owned approximately 0.31% of Cytokinetics worth []

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the Piper Sandler 33 rd Annual Virtual Healthcare Conference taking place November 30, 2021 to December 2, 2021.

Related Stocks: EPZM , MRUS , ADCT , YMAB , MEIP , NTLA , BCRX , CYTK , VSTM , GERN ,

Analysis from GALACTIC-HF Shows Treatment with Omecamtiv Mecarbil Associated with Significant Reduction in the Risk of Stroke

Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q3 2021 Results - Earnings Call Transcript

Cytokinetics (CYTK) delivered earnings and revenue surprises of -26.67% and -0.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

The consensus price target hints at a 47.8% upside potential for Cytokinetics (CYTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2021 at 4:0

The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Cytokinetics (CYTK). While the effectiveness of this highly sought-after metric is questionable, the p

Go-To-Market Strategy Focuses on Educating Healthcare Professionals, Ensuring Managed Care Access, and Enacting Programs for Patient Access, Education and Support